MA27553A1 - Utilisation d'un agoniste de ppar et de metformine pour diminuer les triglycerides seriques - Google Patents
Utilisation d'un agoniste de ppar et de metformine pour diminuer les triglycerides seriquesInfo
- Publication number
- MA27553A1 MA27553A1 MA28301A MA28301A MA27553A1 MA 27553 A1 MA27553 A1 MA 27553A1 MA 28301 A MA28301 A MA 28301A MA 28301 A MA28301 A MA 28301A MA 27553 A1 MA27553 A1 MA 27553A1
- Authority
- MA
- Morocco
- Prior art keywords
- ppar
- metformin
- agonist
- serum triglycerides
- decrease serum
- Prior art date
Links
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title abstract 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003105 metformin Drugs 0.000 title abstract 3
- 210000002966 serum Anatomy 0.000 title abstract 3
- 150000003626 triacylglycerols Chemical class 0.000 title abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Utilisation d'un agoniste de PPAR(alpha) et de metformine pour diminuer les triglycérides sériques FOURNIER LABORATORIES IRELAND. La présente invention concerne l'utilisation combinée d'un agoniste de PPAR(alpha) et de metformine pour abaisser les triglycérides sériques.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02292940A EP1424070A1 (fr) | 2002-11-28 | 2002-11-28 | Combinaison d'un agoniste de PPAR-alpha et de metformine pour la réduction du taux de triglycérides sériques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27553A1 true MA27553A1 (fr) | 2005-10-03 |
Family
ID=32241358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28301A MA27553A1 (fr) | 2002-11-28 | 2005-05-26 | Utilisation d'un agoniste de ppar et de metformine pour diminuer les triglycerides seriques |
Country Status (22)
Country | Link |
---|---|
US (2) | US20060142397A1 (fr) |
EP (2) | EP1424070A1 (fr) |
JP (1) | JP2006508995A (fr) |
CN (1) | CN1777417B (fr) |
AT (1) | ATE362362T1 (fr) |
AU (1) | AU2003288175B2 (fr) |
BR (1) | BR0316810A (fr) |
CA (1) | CA2507894C (fr) |
CY (1) | CY1106749T1 (fr) |
DE (1) | DE60313886T2 (fr) |
DK (1) | DK1569634T3 (fr) |
EA (1) | EA009772B1 (fr) |
ES (1) | ES2287546T3 (fr) |
HK (1) | HK1077755A1 (fr) |
MA (1) | MA27553A1 (fr) |
MX (1) | MXPA05005707A (fr) |
NO (1) | NO20052549L (fr) |
PT (1) | PT1569634E (fr) |
SI (1) | SI1569634T1 (fr) |
TN (1) | TNSN05148A1 (fr) |
WO (1) | WO2004047831A2 (fr) |
ZA (1) | ZA200504345B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
EP1457206A1 (fr) * | 2003-03-13 | 2004-09-15 | Fournier Laboratories Ireland Limited | Utilisation combinée d'un fibrate et de l'orlistat pour le traitement de l'obésité |
EP1559419A1 (fr) * | 2004-01-23 | 2005-08-03 | Fournier Laboratories Ireland Limited | Composition pharmaceutique contenant une combinaison de mefformine et d'un fibrate et les procédés pour les obtenir |
FR2896160B1 (fr) * | 2006-01-13 | 2008-04-25 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agonistes du ppar alpha. |
US8883721B2 (en) * | 2009-05-12 | 2014-11-11 | Mcgill University | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
US9724381B2 (en) | 2009-05-12 | 2017-08-08 | The Administrators Of The Tulane Educational Fund | Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof |
EP2582715B1 (fr) | 2010-06-16 | 2018-11-28 | The Administrators of the Tulane Educational Fund | Antagonistes du récepteur du secrétagogue de l'hormone de croissance et leurs utilisations |
FR3050112B1 (fr) * | 2016-04-15 | 2020-09-04 | Soc Civ Immobiliere Gecinq | Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques |
CN107496397A (zh) * | 2016-06-14 | 2017-12-22 | 重庆安格龙翔医药科技有限公司 | 一种二甲双胍与非诺贝酸的复合物及其制剂 |
FR3056908B1 (fr) * | 2016-09-30 | 2019-04-19 | Nashpharm | Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie |
CN111374093A (zh) * | 2018-12-28 | 2020-07-07 | 高倩 | 超级肥胖小鼠的构建与鉴定方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT323195B (de) * | 1973-03-16 | 1975-06-25 | Hurka Wilhelm | Verfahren zur herstellung neuer salze von biguaniden |
FR2275199A1 (fr) * | 1974-06-19 | 1976-01-16 | Cerpha | (chloro-4 phenoxy) isobutyrate de dimethylbiguanide, son procede de preparation et medicaments contenant ce produit comme principe actif |
US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
EP1011651B1 (fr) * | 1996-02-02 | 2005-04-27 | Merck & Co., Inc. | Methode de traitement du diabete et d'etats pathologiques associes |
WO1998005331A2 (fr) * | 1996-08-02 | 1998-02-12 | Ligand Pharmaceuticals Incorporated | Prevention ou traitement de diabetes non insulinodependants ou de maladies cardiovasculaires avec des modulateurs ppar |
FR2774591B1 (fr) * | 1998-02-12 | 2000-05-05 | Lipha | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
US5942500A (en) * | 1998-04-27 | 1999-08-24 | Perry; Stephen C. | Dietary composition to reduce dietary fats |
FR2796940B1 (fr) * | 1999-07-26 | 2005-04-08 | Lipha | Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
US6498193B2 (en) * | 1999-12-22 | 2002-12-24 | Trustees Of Dartmouth College | Treatment for complications of type 2 diabetes |
US6569879B2 (en) * | 2000-02-18 | 2003-05-27 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
US20030092736A1 (en) * | 2001-05-30 | 2003-05-15 | Cheng Peter T. | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
AU2003296895A1 (en) * | 2002-08-20 | 2004-05-04 | The Regents Of The University Of California | Combination therapy for controlling appetites |
-
2002
- 2002-11-28 EP EP02292940A patent/EP1424070A1/fr not_active Withdrawn
-
2003
- 2003-11-26 EA EA200500691A patent/EA009772B1/ru not_active IP Right Cessation
- 2003-11-26 PT PT03780062T patent/PT1569634E/pt unknown
- 2003-11-26 CA CA2507894A patent/CA2507894C/fr not_active Expired - Fee Related
- 2003-11-26 DE DE60313886T patent/DE60313886T2/de not_active Expired - Lifetime
- 2003-11-26 MX MXPA05005707A patent/MXPA05005707A/es active IP Right Grant
- 2003-11-26 BR BR0316810-7A patent/BR0316810A/pt not_active IP Right Cessation
- 2003-11-26 ES ES03780062T patent/ES2287546T3/es not_active Expired - Lifetime
- 2003-11-26 CN CN2003801044454A patent/CN1777417B/zh not_active Expired - Fee Related
- 2003-11-26 US US10/536,660 patent/US20060142397A1/en not_active Abandoned
- 2003-11-26 AT AT03780062T patent/ATE362362T1/de active
- 2003-11-26 WO PCT/EP2003/013302 patent/WO2004047831A2/fr active IP Right Grant
- 2003-11-26 EP EP03780062A patent/EP1569634B8/fr not_active Expired - Lifetime
- 2003-11-26 JP JP2004554485A patent/JP2006508995A/ja active Pending
- 2003-11-26 SI SI200330898T patent/SI1569634T1/sl unknown
- 2003-11-26 DK DK03780062T patent/DK1569634T3/da active
- 2003-11-26 AU AU2003288175A patent/AU2003288175B2/en not_active Ceased
-
2005
- 2005-05-26 MA MA28301A patent/MA27553A1/fr unknown
- 2005-05-26 NO NO20052549A patent/NO20052549L/no not_active Application Discontinuation
- 2005-05-27 TN TNP2005000148A patent/TNSN05148A1/fr unknown
- 2005-05-27 ZA ZA200504345A patent/ZA200504345B/en unknown
- 2005-11-08 HK HK05109941A patent/HK1077755A1/xx not_active IP Right Cessation
-
2007
- 2007-07-20 CY CY20071100972T patent/CY1106749T1/el unknown
-
2010
- 2010-02-12 US US12/705,155 patent/US20100144874A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1777417B (zh) | 2010-10-06 |
WO2004047831A2 (fr) | 2004-06-10 |
CA2507894C (fr) | 2011-01-04 |
EP1424070A1 (fr) | 2004-06-02 |
SI1569634T1 (sl) | 2007-10-31 |
EP1569634B8 (fr) | 2007-08-29 |
ZA200504345B (en) | 2006-08-30 |
CA2507894A1 (fr) | 2004-06-10 |
JP2006508995A (ja) | 2006-03-16 |
EP1569634A2 (fr) | 2005-09-07 |
EP1569634B1 (fr) | 2007-05-16 |
CN1777417A (zh) | 2006-05-24 |
DE60313886D1 (de) | 2007-06-28 |
MXPA05005707A (es) | 2005-07-26 |
BR0316810A (pt) | 2005-10-18 |
US20100144874A1 (en) | 2010-06-10 |
AU2003288175B2 (en) | 2008-11-13 |
DE60313886T2 (de) | 2008-01-17 |
AU2003288175A1 (en) | 2004-06-18 |
ES2287546T3 (es) | 2007-12-16 |
DK1569634T3 (da) | 2007-09-10 |
EA009772B1 (ru) | 2008-04-28 |
HK1077755A1 (en) | 2006-02-24 |
PT1569634E (pt) | 2007-08-22 |
CY1106749T1 (el) | 2012-05-23 |
ATE362362T1 (de) | 2007-06-15 |
WO2004047831A3 (fr) | 2005-02-24 |
US20060142397A1 (en) | 2006-06-29 |
EA200500691A1 (ru) | 2005-12-29 |
NO20052549L (no) | 2005-06-10 |
TNSN05148A1 (fr) | 2007-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27553A1 (fr) | Utilisation d'un agoniste de ppar et de metformine pour diminuer les triglycerides seriques | |
DK1268847T3 (da) | Ubiquitin-ligaseassay | |
DE60219877D1 (de) | Abdeckung für Leuchttastschalter | |
BR9608032A (pt) | Sulfonamidas contendo thf inibidoras de aspartil protease | |
DE60231163D1 (de) | Negativ aufladbarer Toner | |
DE60231574D1 (de) | Pflegemittel für kontaktlinsen enthaltend dexpanthenol | |
AU2001245927A1 (en) | Lexical analysis of telephone conversations with call center agents | |
IL157171A0 (en) | Broadspectrum 2-(substituted-amino) -benzothiazole sulfonamide hiv protease inhibitors | |
DE60140929D1 (de) | Immunoassay für HIV-Protease-Hemstoffe | |
FR2813478B1 (fr) | Repartition predictive d'appels entre des centres de renseignement | |
FR2844453B1 (fr) | Utilisation de pre-biotiques pour la prevention de l'installation du diabete de type ii | |
HUP0303744A3 (en) | Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors and pharmaceutical compositions containing them | |
FI20011263A0 (fi) | Ryhmäpuhelun hallintamekanismi | |
FR2819563B1 (fr) | Visco-accouplement avec frein pour sa bague d'accouplement | |
ATE302261T1 (de) | Stabilisierte transparente seifenzusammensetzung | |
FR2846434B1 (fr) | Ecran pour lunettes et pieces pour la fabrication d'un tel ecran | |
FR2700886B1 (fr) | Membrane élastique d'étanchéité pour bouton poussoir. | |
FI103623B1 (fi) | Puhelimen luurin tilan ilmaisu | |
FR2821556B1 (fr) | Utilisation de lipopeptides pour l'immunotherapie des sujets vih+ | |
ITNA20010019V0 (it) | "calendario con fogli recanti parti di un'immagine compatibile". | |
DE29819682U1 (de) | Sprachbildhalter | |
FR2813793B1 (fr) | Utilisation de lipopeptides pour l'immunotherapie des sujets vih+ | |
DK1226122T3 (da) | Bicykliske vasopressin-agonister | |
DE29700825U1 (de) | Elastischer Ring für optische Einschraubvorsätze | |
UA32947A (uk) | Горілка особлива |